Comparison of 2-Methoxyestradiol and Methotrexate Effects on Non-Hodgkin's B-Cell Lymphoma

Abstract

Purpose: Methotrexate (MTX) is the most commonly used chemotherapeutic agent to treat primary central nervous system lymphoma (PCNSL) and intraocular lymphoma (IOL). 2-Methoxyestradiol (2ME2) is a potent antitumor and anti-angiogenesis agent which, unlike other cytotoxic drugs, has minimal toxicity. In this study, anti-proliferative, apoptotic, and cell-cycle effects of 2ME2 and MTX were compared to evaluate 2ME2 efficacy in human lymphoma cells, models for non-Hodgkin B cell lymphomas. Methods: The cells were cultured and incubated with varying concentrations of 2ME2 or MTX. A tetrazolium-based colorimetric assay was used to quantify the anti-proliferative effects of 2ME2 and MTX using a microplate reader. To detect apoptotic and cell cycle distribution changes induced by 2ME2 and MTX, the cells were stained with Annexin V-FITC and/or propidium iodide (PI) and analyzed by flow cytometry. Results: Lymphoma cell proliferation was inhibited by 50% at concentrations ranging from 0.4 to 1 μ M for 2ME2 and 0.06 to 0.2 μ M for MTX. Induction of apoptosis by 2ME2 and MTX was observed in the tested cells. 2ME2 was a G2/M-phase specific blocker whereas MTX was an S-phase specific blocker in cell cycle analyses. At 1 μ M concentration, 2ME2 and MTX showed similar anti-proliferative effect on the lymphoma cell lines. In previously reported studies, for normal endothelial cells, 1 μ M 2ME2 showed no appreciable toxicity, while MTX at this same concentration exhibited significant cytotoxicity. 2ME2 at a therapeutic target concentration of 1 μ M may be an effective and relatively non-toxic drug for the treatment of PCNSL with IOL. Conclusions: Our study of the effect of 2ME2 and MTX on anti-proliferation, apoptosis, and cell cycling suggests that 2ME2 is a potential agent for treating PCNSL and IOL.